The Clinical Research Core is a newly created resource for the SPORE. It now combines the PatientRegistry activities that have been ongoing and supported by the SPORE in the previous funding period withthe new activities in the proposed funding period related to support for clinical studies in all four translationalresearch projects. The directors of this Core have extensive experience in studies of human subjects andrecruitment of patients to research protocols, both for observational studies and clinical trials. To date, thepancreatic cancer SPORE'S Patient Registry activities have been very productive, with accrual of 2279consented subjects (~325/year), using ultra-rapid case finding, a necessary method for this rapidly fatalcancer. Mayo Clinic diagnoses and/or treats an estimated 570 pancreatic cancer patients per year across itsthree campuses. There are 1612 pancreatic cancer patients in the Registry, of which >50% have pancreatictissue biospecimens accessioned in the Tissue Core. In addition, the Registry includes data on 1513 age,sex, race, and region-matched healthy controls. It will coordinate its activities very closely with theBiostatistics Core and the Tissue Core to ensure the highest quality annotated biospecimens and pancreaticcancer database for research. The infrastructure for patient recruitment in the Registry will be used to recruitsubjects for Project 2. The SPORE will conduct early phase clinical trials in Projects 1, 3, and 4 in the nextfunding period. It will utilize the Cancer Center-supported Clinical Research Office (CRO) shared resource tooperationalize the trials. The Clinical Research Core will 1) perform the necessary clinical trial managementsupport activities; 2) centrally coordinate all activities with the infrastructure of the Cancer Center CRO toensure smooth execution of the SPORE'S clinical trials; 3) perform all patient recruitment activities for thetriple tracer test for Project 2; 4) recruit new onset diabetics to support the validation study in Project 2; 5)maintain the ultra-rapid case recruitment and registry of pancreatic cancer patients at all three Mayocampuses; and 6) serve as a resource to future developmental research and career development researchprojects. The close coordination and oversight of the most senior leaders of the SPORE will ensure that allclinical research activities are performed with the highest level of research integrity and adherence to allhuman subjects regulations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA102701-06
Application #
7510973
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-07-01
Project End
2013-06-30
Budget Start
2008-07-01
Budget End
2009-08-31
Support Year
6
Fiscal Year
2008
Total Cost
$157,692
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Zhang, Mingfeng; Lykke-Andersen, Soren; Zhu, Bin et al. (2018) Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. Gut 67:521-533
Kanamori, Karina S; de Oliveira, Guilherme C; Auxiliadora-Martins, Maria et al. (2018) Two Different Methods of Quantification of Oxidized Nicotinamide Adenine Dinucleotide (NAD+) and Reduced Nicotinamide Adenine Dinucleotide (NADH) Intracellular Levels: Enzymatic Coupled Cycling Assay and Ultra-performance Liquid Chromatography (UPLC)-Mass Bio Protoc 8:
Hu, Chunling; Hart, Steven N; Polley, Eric C et al. (2018) Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA 319:2401-2409
Orozco, Carlos A; Martinez-Bosch, Neus; Guerrero, Pedro E et al. (2018) Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A 115:E3769-E3778
Radecki Breitkopf, Carmen; Wolf, Susan M; Chaffee, Kari G et al. (2018) Attitudes Toward Return of Genetic Research Results to Relatives, Including After Death: Comparison of Cancer Probands, Blood Relatives, and Spouse/Partners. J Empir Res Hum Res Ethics 13:295-304
Antwi, Samuel O; Fagan, Sarah E; Chaffee, Kari G et al. (2018) Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. J Natl Cancer Inst :
Cobo, Isidoro; Martinelli, Paola; Flández, Marta et al. (2018) Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas. Nature 554:533-537
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Chaker, Mahmoud; Minden, Audrey; Chen, Suzie et al. (2018) Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opin Ther Targets 22:9-17

Showing the most recent 10 out of 336 publications